News
August 12, 2022

Regenstrief Institute appoints Nist interim CIO

Robert Nist

The Regenstrief Institute has appointed Robert L. Nist as interim chief information officer (CIO), commencing August 17. He is a highly experienced executive at the intersection of technology, the pharmaceutical industry and healthcare.

Nist began working as an independent consultant after a nearly four-decade career with Eli Lilly and Company and Rockwell Automation. He spent the majority of his career at Lilly, where he held numerous positions including vice president and divisional CIO for medicines development, manufacturing, quality and connected care. Prior to that, he served as vice president and CIO for diabetes manufacturing and quality at Elanco Animal Health. At Rockwell he served as vice president for technology management.

“I am pleased that this highly regarded professional, who has a deep understanding of how to use technology to promote human health, has agreed to join us on an interim basis to help lead our innovative organization,” said Regenstrief Interim President and Chief Executive Officer Susan Hickman, PhD. “His business acumen, healthcare expertise and technology skills are a strong fit for our organization. We look forward to working with Bob and benefiting from his considerable strategic, tech savvy leadership.”

Nist earned bachelor of science degrees in chemistry and chemical engineering from Purdue University, where he also earned a master of science degree in computer and information science. He is a current member of Purdue’s Engineering Ethics and Compliance Advisory Group and Anderson University’s Engineering Advisory Group.

Related News

image of pregnant woman with vaccine acting as protection from COVID virus

National CDC-funded study confirms that mRNA vaccines protect against serious COVID-19 during pregnancy

The first large, real-world study of the effectiveness of mRNA COVID-19 vaccines during pregnancy found these vaccines, especially two

Thomas Imperiale

Journal editorial: Regenstrief researcher calls for tailoring colorectal cancer screening for 45-to-49-year-olds

It’s been a year since national recommendations issued by the American Cancer Society and the U.S. Multi-Society Task Force

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Regenstrief Vice President for Data and Analytics Shaun Grannis, M.D., M.S., discusses the questions that will be investigated in

Screening tools co-developed by Regenstrief Institute research scientist help clinicians assess and treat vexing symptoms

Screening tools co-developed by Regenstrief Institute research scientist help clinicians assess and treat vexing symptoms

Widely used scales measure pain, depression, anxiety, suicide risk, cancer fatigue and now symptoms associated with a common dental